Flash Report of the Interim Financial Results for the Fiscal Term Ended June 30, 2007

TOKYO, July 18, 2007-On July 19, 2007 (Central European Time), the Roche Group, which incorporates Roche Pharmholding B.V., the parent company of Chugai Pharmaceutical Co., Ltd. ("Chugai"), will announce its half year results for fiscal year 2007 based on International Financial Reporting Standards. As some financial information on Chugai will be included in the announcement, Chugai hereby announces its flash report of the interim financial results for the fiscal term ending in December 2007 (January 1, 2007 to December 31, 2007) in pursuit of timely and fair disclosure to its shareholders and investors, prior to the announcement of its parent company.

The announcement of full financial statements is scheduled on July 31, 2007. Interim Financial Results for the fiscal term ended June 2007 (January to June 2007)
(Consolidated) (Millions of yen)
Figures are rounded to the nearest 100 million.
  Net Sales Operating Income Recurring Profit Net Income
Results for Jan. - Jun., 2007 (A) 170,900 35,800 36,800 21,100
Results for Jan. - Jun., 2006 (B) 152,600 27,400 29,800 18,800
Difference (A-B) 18,300 8,400 7,000 2,300
Rate of Change 12.0% 30.7% 23.5% 12.2%

(Non-consolidated) (Millions of yen)
Figures are rounded to the nearest 100 million.
  Net Sales Operating Income Recurring Profit Net Income
Results for Jan. - Jun., 2007 (A) 163,200 30,500 32,100 19,600
Results for Jan. - Jun., 2006 (B) 146,500 24,200 27,300 17,600
Difference (A-B) 16,700 6,300 4,800 2,000
Rate of Change 11.4% 26.0% 17.6% 11.4%

Consolidated net sales for the first half this year totaled ¥170.9 billion, up 12.0% compared with the same period last year. Sales of our anti-influenza agent Tamiflu increased from the first half last year, due to the government purchase for stockpiling. Overseas sales of Neutrogin, our recombinant human granulocyte colony-stimulating factor (rG-CSF) also increased mainly due to the effect of favorable foreign exchange rate. Moreover, the anti-tumor agent Herceptin, an anti-HER2 monoclonal antibody, and the osteoporosis treatment Evista, showed a steady performance. On the other hand, sales of the mainstay product Epogin, recombinant human erythropoietin, declined due to such factors as the introduction of the flat-sum reimbursement system for dialysis treatment since April 2006. The income from patent royalties, etc. is included in net sales from this fiscal year.

At the profit level, although selling, general and administrative expenses increased due to proactive marketing and promotion activities, operating income, recurring profit and net income all increased compared with the same period last year, due to an increase in gross profit.


Consolidated Statements of Sales for January 1 - June 30, 2007
(Millions of Yen)
Figures are rounded to the nearest 100 million.
  Jan.-Jun., 2006 Jan.-Jun., 2007
Epogin 31,000 28,200
Tamiflu 16,300 23,800
Neutrogin 16,500 18,700
Sigmart 8,600 8,600
Rituxan 8,100 8,500
Herceptin 6,400 7,900
Evista 5,800 7,200
Alfarol 7,000 6,800
Kytril 6,000 6,300
Suvenyl 4,100 5,000
Oxarol 3,500 3,900
Rythmodan 3,200 3,000
Rocephin 2,600 2,700
Renagel 2,300 2,600
Pegasys 3,000 2,400
CellCept 1,400 1,600
Xeloda 1,200 1,300
Copegus - 600
Femara 100 400
Avastin - 300
Actemra 200 200
Others * 25,300 30,900
Total 152,600 170,900
Notes:* Patent royalties income, etc. of ¥7,500 million is included in the figure for Jan. - Jun., 2007.

Name of listed company:   Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Tokyo Stock Exchange)  
Head office: 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo  
Representative: Osamu Nagayama, President & CEO  
Inquiries to: Toshiaki Itagaki, General Manager,
Finance & Accounting Dept.
 
  Tel:+81-(0)3-3281-6611  

Posted: July 2007


View comments

Hide
(web1)